Literature DB >> 23841028

Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties.

Nanaocha Sharma1, Daniele Repetto, Simona Aramu, Silvia Grasso, Isabella Russo, Arianna Fiorentino, Maurizia Mello-Grand, Sara Cabodi, Vijay Singh, Giovanna Chiorino, Emilia Turco, Paola Di Stefano, Paola Defilippi.   

Abstract

p140Cap is an adaptor protein that negatively controls tumor cell properties, by inhibiting in vivo tumor growth and metastasis formation. Our previous data demonstrated that p140Cap interferes with tumor growth and impairs invasive properties of cancer cells inactivating signaling pathways, such as the tyrosine kinase Src or E-cadherin/EGFR cross-talk. In breast cancer p140Cap expression inversely correlates with tumor malignancy. p140Cap is composed of several conserved domains that mediate association with specific partners. Here we focus our attention on two domains of p140Cap, the TER (Tyrosine Enriched Region) which includes several tyrosine residues, and the CT (Carboxy Terminal) which contains a proline rich sequence, involved in binding to SH2 and SH3 domains, respectively. By generating stable cell lines expressing these two proteins, we demonstrate that both TER and CT domains maintain the ability to associate the C-terminal Src kinase (Csk) and Src, to inhibit Src activation and Focal adhesion kinase (Fak) phosphorylation, and to impair in vitro and in vivo tumor cell features. In particular expression of TER and CT proteins in cancer cells inhibits in vitro and in vivo growth and directional migration at a similar extent of the full length p140Cap protein. Moreover, by selective point mutations and deletion we show that the ability of the modules to act as negative regulators of cell migration and proliferation mainly resides on the two tyrosines (Y) inserted in the EPLYA and EGLYA sequences in the TER module and in the second proline-rich stretch contained in the CT protein. Gene signature of cells expressing p140Cap, TER or CT lead to the identification of a common pattern of 105 down-regulated and 128 up-regulated genes, suggesting that the three proteins can act through shared pathways. Overall, this work highlights that the TER and CT regions of p140Cap can efficiently suppress tumor cell properties, opening the perspective that short, defined p140Cap regions can have therapeutic effects.

Entities:  

Keywords:  Csk; Src; breast cancer; cell signaling; colon cancer; lung cancer; p140Cap

Year:  2013        PMID: 23841028      PMCID: PMC3696535     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  13 in total

1.  p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation.

Authors:  L Damiano; P Di Stefano; M P Camacho Leal; M Barba; F Mainiero; S Cabodi; L Tordella; A Sapino; I Castellano; M Canel; M Frame; E Turco; P Defilippi
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

Review 2.  Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging.

Authors:  Alan Serrels; Marta Canel; Valerie G Brunton; Margaret C Frame
Journal:  Cell Adh Migr       Date:  2011-07-01       Impact factor: 3.405

3.  p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation.

Authors:  L Damiano; S E Le Dévédec; P Di Stefano; D Repetto; R Lalai; H Truong; J L Xiong; E H Danen; K Yan; F J Verbeek; E De Luca; F Attanasio; R Buccione; E Turco; B van de Water; P Defilippi
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

4.  SNIP, a novel SNAP-25-interacting protein implicated in regulated exocytosis.

Authors:  L S Chin; R D Nugent; M C Raynor; J P Vavalle; L Li
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

5.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Authors:  Richard M Neve; Koei Chin; Jane Fridlyand; Jennifer Yeh; Frederick L Baehner; Tea Fevr; Laura Clark; Nora Bayani; Jean-Philippe Coppe; Frances Tong; Terry Speed; Paul T Spellman; Sandy DeVries; Anna Lapuk; Nick J Wang; Wen-Lin Kuo; Jackie L Stilwell; Daniel Pinkel; Donna G Albertson; Frederic M Waldman; Frank McCormick; Robert B Dickson; Michael D Johnson; Marc Lippman; Stephen Ethier; Adi Gazdar; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

6.  Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity.

Authors:  Jacek Jaworski; Lukas C Kapitein; Susana Montenegro Gouveia; Bjorn R Dortland; Phebe S Wulf; Ilya Grigoriev; Paola Camera; Samantha A Spangler; Paola Di Stefano; Jeroen Demmers; Harm Krugers; Paola Defilippi; Anna Akhmanova; Casper C Hoogenraad
Journal:  Neuron       Date:  2009-01-15       Impact factor: 17.173

Review 7.  Src kinases as therapeutic targets for cancer.

Authors:  Lori C Kim; Lanxi Song; Eric B Haura
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

8.  p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity.

Authors:  Paola Di Stefano; Laura Damiano; Sara Cabodi; Simona Aramu; Luca Tordella; Alice Praduroux; Roberto Piva; Federica Cavallo; Guido Forni; Lorenzo Silengo; Guido Tarone; Emilia Turco; Paola Defilippi
Journal:  EMBO J       Date:  2007-05-24       Impact factor: 11.598

Review 9.  From modules to medicine: How modular domains and their associated networks can enable personalized medicine.

Authors:  Eric B Haura
Journal:  FEBS Lett       Date:  2012-05-07       Impact factor: 4.124

10.  Mapping of p140Cap phosphorylation sites: the EPLYA and EGLYA motifs have a key role in tyrosine phosphorylation and Csk binding, and are substrates of the Abl kinase.

Authors:  Daniele Repetto; Simona Aramu; Elisabetta Boeri Erba; Nanaocha Sharma; Silvia Grasso; Isabella Russo; Ole N Jensen; Sara Cabodi; Emilia Turco; Paola Di Stefano; Paola Defilippi
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more
  11 in total

1.  MicroRNA-346 functions as an oncogene in cutaneous squamous cell carcinoma.

Authors:  Bin Chen; Wenyan Pan; Xiaoxi Lin; Zhenzhen Hu; Yunbo Jin; Hui Chen; Gang Ma; Yajing Qiu; Lei Chang; Chen Hua; Yun Zou; Yang Gao; Hanru Ying; Dongze Lv
Journal:  Tumour Biol       Date:  2015-09-26

2.  The N-terminal domain of the adaptor protein p140Cap interacts with Tiam1 and controls Tiam1/Rac1 axis.

Authors:  Jennifer Chapelle; Annalisa Baudino; Federico Torelli; Aurora Savino; Alessandro Morellato; Costanza Angelini; Vincenzo Salemme; Giorgia Centonze; Dora Natalini; Marta Gai; Valeria Poli; Thilo Kähne; Emilia Turco; Paola Defilippi
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Integrative Proteo-genomic Analysis to Construct CNA-protein Regulatory Map in Breast and Ovarian Tumors.

Authors:  Weiping Ma; Lin S Chen; Umut Özbek; Sung Won Han; Chenwei Lin; Amanda G Paulovich; Hua Zhong; Pei Wang
Journal:  Mol Cell Proteomics       Date:  2019-07-07       Impact factor: 5.911

4.  miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1.

Authors:  Yushun Gao; Qi Xue; Dali Wang; Minjun Du; Yanjiao Zhang; Shugeng Gao
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

5.  Overexpression of Srcin1 contributes to the growth and metastasis of colorectal cancer.

Authors:  Mengnan Zhang; Feng Ma; Ruyi Xie; Yao Wu; Meiyan Wu; Pei Zhang; Ying Peng; Jinjun Zhao; Jing Xiong; Aimin Li; Cheng Kequan; Yali Zhang; Side Liu; Jide Wang; Xueqing Chen
Journal:  Int J Oncol       Date:  2017-04-05       Impact factor: 5.650

6.  The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries.

Authors:  Silvia Grasso; Jennifer Chapelle; Vincenzo Salemme; Simona Aramu; Isabella Russo; Nicoletta Vitale; Ludovica Verdun di Cantogno; Katiuscia Dallaglio; Isabella Castellano; Augusto Amici; Giorgia Centonze; Nanaocha Sharma; Serena Lunardi; Sara Cabodi; Federica Cavallo; Alessia Lamolinara; Lorenzo Stramucci; Enrico Moiso; Paolo Provero; Adriana Albini; Anna Sapino; Johan Staaf; Pier Paolo Di Fiore; Giovanni Bertalot; Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Manuela Iezzi; Paola Di Stefano; Emilia Turco; Paola Defilippi
Journal:  Nat Commun       Date:  2017-03-16       Impact factor: 14.919

7.  Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells.

Authors:  Paola Bagnato; Alessia Castagnino; Katia Cortese; Maria Bono; Silvia Grasso; Grazia Bellese; Tiziana Daniele; Richard Lundmark; Paola Defilippi; Patrizio Castagnola; Carlo Tacchetti
Journal:  Oncotarget       Date:  2017-05-08

Review 8.  The p140Cap adaptor protein as a molecular hub to block cancer aggressiveness.

Authors:  Vincenzo Salemme; Costanza Angelini; Jennifer Chapelle; Giorgia Centonze; Dora Natalini; Alessandro Morellato; Daniela Taverna; Emilia Turco; Ugo Ala; Paola Defilippi
Journal:  Cell Mol Life Sci       Date:  2020-10-20       Impact factor: 9.261

9.  SRCIN1 Suppressed Osteosarcoma Cell Proliferation and Invasion.

Authors:  Peng Wang; Hu Wang; Xiaotao Li; Ying Liu; Chengbin Zhao; Daling Zhu
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

10.  Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1.

Authors:  Ling Guo; Ye Zhu; Liandi Li; Shufen Zhou; Guohua Yin; Guanghao Yu; Hujun Cui
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.